34th week of 2020 patent applcation highlights part 10 |
Patent application number | Title | Published |
20200261532 | Chinese Medicine Composition for Treating Gastric Reflux - A Chinese medicine composition for treating gastric reflux, comprising the following raw materials in parts by weight: 2-15 g of turmeric root tuber, 2-10 g of | 2020-08-20 |
20200261533 | Highly Absorbable Oral Tyrosine Formulation - Provided is a tyrosine formulation excellent in bioabsorbability of tyrosine when ingested orally. An oral formulation with improved bioabsorbability of tyrosine, including glycyltyrosine or a salt thereof or a solvate thereof. | 2020-08-20 |
20200261534 | NEW TREATMENTS OF MULTIPLE MYELOMA - The present invention relates to the field of oncology. More specifically, it relates to the use of peptidomimetic compounds in the treatment of multiple myeloma, especially in refractory or relapsing multiple myeloma and/or in combination with other antitumoral agents. | 2020-08-20 |
20200261535 | FLAGELLIN RELATED POLYPEPTIDES AND USES THEREOF - The use of flagellin and flagellin related polypeptide for the protection of mammals from the effects of apoptosis is described. | 2020-08-20 |
20200261536 | COMPOSITIONS AND RELATED METHODS FOR CONTROLLING VECTOR-BORNE DISEASES - Provided herein are methods and compositions useful for human health, e.g., for targeting one or more microorganisms resident in a host insect (e.g., arthropod, e.g., insect, e.g., pathogen vector), the modulation resulting in a decrease in the fitness of the host. The invention features a composition that includes a modulating agent (e.g., phage, peptide, small molecule, antibiotic, or combinations thereof) that can alter the host's microbiota in a manner that is detrimental to the host. By disrupting microbial levels, microbial activity, microbial metabolism, or microbial diversity, the modulating agent described herein may be used to decrease the fitness of a variety of insects that carry vector-bore pathogens that cause disease in humans. | 2020-08-20 |
20200261537 | COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS - The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects. | 2020-08-20 |
20200261538 | METHOD FOR THE TREATMENT OR PREVENTION OF OSTEOARTHRITIS - The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide is between 12 and 28 amino acids in length and comprises an amino acid sequence according to SEQ ID NO: 16 or a variant thereof according to formula 2, wherein the amino acid sequence of said peptide is comprised in SEQ ID NO: 34 or a variant thereof according to formula 1. | 2020-08-20 |
20200261539 | METHOD FOR THE TREATMENT OR PREVENTION OF OSTEOARTHRITIS - The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide consists of an amino acid sequence according to SEQ ID NO: 18 or an analogue thereof, wherein the analogue is a peptide consisting of an amino acid sequence according to formula 1 (SEQ ID NO: 29), or a fragment thereof wherein the fragment consists of at least 10 consecutive amino acids of SEQ ID NO: 18 or an amino acid sequence according to formula 1. | 2020-08-20 |
20200261540 | Method for predicting and monitoring the efficacy of low-dose IL-2 and hydroxychloroquine therapy in autoimmune diseases and its long-term use in autoimmune-related conditions - A method of inhibiting or treating systemic lupus erythematosus (SLE) and/or primary Sjögren's Syndrome (pSS) in a subject in need thereof is disclosed. The method calls for administering to the subject a therapeutically effective low-dose amount of interleukin-2 and hydroxychloroquine alone or in combination with a therapeutically effective amount of another disease-modifying antirheumatic drug. That combination results in inhibiting or treating SLE and/or pSS in the subject. | 2020-08-20 |
20200261541 | METHODS OF TREATING MILD BRAIN INJURY - The present disclosure provides methods for treating mild brain injury and other neurological disorders in a subject in need thereof, comprising administering to the subject an effective amount of a compound comprising a ghrelin or ghrelin variant. | 2020-08-20 |
20200261542 | FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO - The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis. | 2020-08-20 |
20200261543 | COMBINATION THERAPY FOR TREATMENT OF BONE DISORDERS - Provided herewith is the use of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-2 (GLP-2) for treatment of bone disorders such as osteoporosis. | 2020-08-20 |
20200261544 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier - The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts. | 2020-08-20 |
20200261545 | PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST AN AGENT SELECTED FROM MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYCLIC ACID AND PARACETAMOL - The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes. | 2020-08-20 |
20200261546 | METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF) - The present invention relates to a method for prophylactic treatment of spontaneous bleeding in a subject with severe von Willebrand Disease comprising administering a therapeutic amount of recombinant von Willebrand Factor (rVWF) to the subject. | 2020-08-20 |
20200261547 | CONTROLLED RELEASE SYSTEM FOR PULMONARY DELIVERY OF SURFACTANT PROTEIN D - A controlled release system including surfactant protein D (SPD) and a carrier suitable for controlled release that can be polylactic-co-glycolic acid (PLGA). The system can be in the form of a nanoparticle. A pharmaceutical composition including the system and a pharmaceutically acceptable carrier. Methods of treatment of a disease, disorder or condition associated with a decreased level of SPD in a subject, or for pulmonary delivery of SPD, include administering the pharmaceutical composition to a subject in need of such treatment. | 2020-08-20 |
20200261548 | METHODS OF TREATING MICROBIAL INFECTION AND INFLAMMATION - Methods of treating or preventing microbial infection in a subject in need of treatment by administering a therapeutically effective amount of ergothioneine, or functional analog, or prodrug, or salt thereof. Ergothioneine may be advantageously administered in conjunction with lactoferrin. | 2020-08-20 |
20200261549 | METHODS OF TREATING AND PROTECTING AGAINST CARDIAC DISEASE, CARDIOVASCULAR DISEASE AND RELATED CONDITIONS AND SYMPTOMS - Provided are methods of treating subjects having, or at risk of having, heart disease, cardiovascular disease, coronary artery disease, cerebrovascular disease, acute or chronic renal disease, and/or symptoms thereof with certain therapeutically effective doses and dosing regimens comprising an isolated and purified lecithin-cholesterol acyltransferase (LCAT) enzyme, in particular, a recombinant human LCAT (rhLCAT) enzyme, e.g., MEDI6012. The methods involving administration of the described doses of rhLCAT increase serum levels of high density lipoprotein (HDL) and apolipoprotein A1 (apoA1) and decrease, or do not appreciably increase, serum levels of apolipoprotein B in the treated subjects, thus affording treatment of heart disease, heart-related diseases and coronary artery disease. The methods involving the described dosing regimens and doses of rhLCAT or MEDI6012 administered to a subject further provide cardio-, myocardio- and cardiovascular protection for the subject, including protection against ischemic stroke, myocardiocyte apoptosis, atherosclerosis progression and the like. | 2020-08-20 |
20200261550 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING RHOA DOMINANT NEGATIVE FORMS - The present invention provides compositions and methods for treating cancers with reduced or absent CDH1 using a RHOA dominant negative polypeptide or biologically active fragment thereof, and/or a nucleic acid encoding a RHOA dominant negative polypeptide or biologically active fragment thereof. | 2020-08-20 |
20200261551 | RESTORATION OF TUMOR SUPPRESSION USING MRNA-BASED DELIVERY SYSTEM - Compositions and methods for treating cancer that include administering a therapeutically effective amount of a tumor suppressor mRNA complexed with a delivery vehicle as described herein, e.g., a nanoparticle. | 2020-08-20 |
20200261552 | Pharmaceutical Composition Containing Carbohydrate Modifying Enzyme and Method of Curing Dendritic Cell Immunoreceptor-Related Disease Using Pharmaceutical Composition - Provided are: a pharmaceutical composition for curing, treating, or preventing a disease involving a biological mechanism controlled by a dendritic cell immunoreceptor, in which the pharmaceutical composition contains a carbohydrate modifying enzyme as an active ingredient; and a method of curing, treating, or preventing a disease involving a biological mechanism controlled by a dendritic cell immunoreceptor. | 2020-08-20 |
20200261553 | COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MILK THISTLE EXTRACT OR POWDER - The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extract or powder. The invention also relates to the combination of a broccoli extract or powder and a milk thistle extract or powder. The invention provides compositions and methods relating to these combinations. | 2020-08-20 |
20200261554 | FACTOR IX POLYPEPTIDE FORMULATIONS - The present invention provides formulations comprising a Factor IX-FcRn Binding Partner (FIXFBP) polypeptide, and methods of administering FIXFBP. | 2020-08-20 |
20200261555 | OPTIMIZATION OF ENZYME REPLACEMENT THERAPY FOR TREATMENT OF HOMOCYSTINURIA - The present invention provides a method of PEGylating a human truncated cystathionine β-synthase protein containing a mutation of a cysteine to a serine at amino acid position 15 (htCBS C15S). The htCBS C15S was PEGylated with one of 5 kDa, 10 kDa, or 20 kDa NHS ester PEG molecules. In-process monitoring of the PEGylation process was used in the method to reduce levels of unPEGylated htCBS C15S and htCBS C15S with insufficient PEGylation. Administration of the PEGylated htCBS C15S had efficacy throughout the course of treatment for homocystinuria. | 2020-08-20 |
20200261556 | C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY - Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed. | 2020-08-20 |
20200261557 | GLYCOSIDASE REGIMEN FOR TREATMENT OF INFECTIOUS DISEASE - In various aspects, the invention relates to immune tolerant glycosidase therapy. The invention provides methods for treating or preventing infectious disease, including chronic viral infections, and highly contagious infectious agents that present an ongoing challenge for the immune system. The compositions and treatment regimens find use with other antiviral or antimicrobial therapies, as well as in conjunction with vaccination to boost effectiveness and/or extend the duration of protective effect. In certain embodiments, the regimen described herein reduces or eliminates the need for administration of other traditional antiviral or antimicrobial therapies. In various embodiments, the invention finds use in immunocompromised patients to boost immune function. | 2020-08-20 |
20200261558 | Vaccines Against Leishmania Infection - A vaccine composition for treating and preventing infection by protozoans is disclosed. The vaccine composition comprises carbohydrates and/or peptides present on the surface of the protozoan, optionally bound to an immunogenic protein nanoparticle. | 2020-08-20 |
20200261559 | COMPOSITIONS AND METHODS OF TREATING CANCER AND INFECTIONS USING BACTERIOPHAGE AND ITS MUTANTS - Provided herein are vaccine composition comprising an antigen conjugated to a capsid, wherein the capsid comprises wild type or native sequence. Provided herein are also vaccine composition comprising an antigen conjugated to a capsid, wherein said capsid comprises at least one mutation, such as a non-natural mutation. Such compositions are useful in the treatment and prevention of pathogenic infections, inflammatory diseases, and neurodegenerative disease, and cancer, among others. | 2020-08-20 |
20200261560 | PRECISION GLYCOCONJUGATES AS THERAPEUTIC TOOLS - The present description relates to glycoconjugates, glycoconjugate immunogens and glycoconjugate vaccines comprising carbohydrate antigens coupled to immunogenic carrier proteins, or materials used for detection and screening of resulting antibodies. Improved methods of more directly and precisely conjugating carbohydrate antigens to free thiol groups of immunogenic carrier proteins are described, including “click-chemistry” approaches based on photocatalytic thiol-ene reactions. | 2020-08-20 |
20200261561 | PLASMODIUM FALCIPARUM AND PLASMODIUM VIVAX VACCINE - The present invention relates to a vaccine V comprising (A) at least one isolated polypeptide strand P comprising or consisting of at least nine consecutive amino acid moieties of the repetitive organellar protein, putative of Plasmodium falciparum or the hypothetical protein PVNG_04523 of | 2020-08-20 |
20200261562 | COMPOSITION AND METHODS OF MAKING AND USING LEPTOSPIRAL LPS - The disclosure provides a method to isolate and use, e.g., in a vaccine, high molecular weight lipopolysaccharide, e.g., from | 2020-08-20 |
20200261563 | CUTANEOUS PAPILLOMA VIRUS VACCINE - The present invention relates to an immunogenic polypeptide comprising a multitude of papillomavirus (PV) L2 N-terminal peptides corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least four different cutaneous HPV genotypes; and to the aforesaid immunogenic polypeptide for use in medicine and for use in vaccination of a subject against cutaneous HPV infection and/or mucosal HPV infection. The present invention further relates to a polynucleotide encoding the aforesaid immunogenic polypeptide and to vectors, host cells, methods for producing an antibody, as well as antibodies related thereto. | 2020-08-20 |
20200261564 | MEASUREMENT OF AFUCOSYLATED IGG FC GLYCANS AND RELATED TREATMENT METHODS - The present disclosure provides methods related to determining the level of afucosylated Fc glycans in IgG antibodies in a biological sample from a subject. This level can be used in methods aimed at monitoring and/or treating subject suffering from an acute flavivirus infection and/or who are at risk for progression to clinically significant infection or disease. This level can also be used in a vaccination method to ensure that those who receive a flavivirus vaccine have a reduced risk of reacting to the vaccine be developing clinically significant infection or disease. The disclosure also provides treatment methods based on inhibiting FcγRIIA or FcγRIIIA receptor signaling. Also provided are novel cell lines that are useful in measuring afucosylated Fc glycans. | 2020-08-20 |
20200261565 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS - Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided. | 2020-08-20 |
20200261566 | PORCINE PARAINFLUENZA VIRUS COMPOSITIONS AND RELATED METHODS - The present disclosure provides the complete nucleotide sequence for porcine parainfluenza virus 1. Immunogenic compositions comprising portions of the nucleotide sequence and proteins expressed therefrom are also provided. | 2020-08-20 |
20200261567 | Vaccine Adjuvant Comprising Lipopeptide-Inserted Liposome as Effective Ingredient and Use Thereof - The present invention relates to a recombinant herpes zoster vaccine comprising liposome and lipopeptide and a method for preparing the same. More particularly, a vaccine composition according to the present invention, prepared using Lipo-Pam, which is a composite adjuvant comprising a liposome and various kinds of lipopeptides, and a varicella-zoster virus gE antigen, a Japanese encephalitis virus gE antigen, or a seasonal inactivated influenza virus antigen, highly induces a cell-mediated immune response as well as a humoral immune response so that the composition of the present invention can be commercially useful. | 2020-08-20 |
20200261568 | NASAL HEPATITIS B VACCINE COMPOSITION AND METHOD FOR PRODUCING SAME - The present invention relates to a hepatitis B vaccine composition for spray-administration to nasal mucosa for preventing and treating hepatitis B, which comprises hepatitis B antigen and carboxy vinyl polymer. | 2020-08-20 |
20200261569 | USE OF ADJUVANTS FOR THE PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES - The invention provides an adjuvant for use in the prevention and/or treatment of an autoimmune disease. | 2020-08-20 |
20200261570 | IMMUNOPOTENTIATOR, FOOT-AND-MOUTH DISEASE INACTIVATED VACCINE AND PREPARATION METHOD THEREOF - A compound immunopotentiator and application thereof relates to the preparation of the compound immunopotentiator and the application thereof in a foot-and-mouth disease vaccine of pigs. The foot-and-mouth disease vaccine of pigs is taken as a research subject, and on this basis, several immunopotentiators having obvious immunopotentiating effects are selected for the compound immunopotentiator, and an antigen/vaccine is mixed with the immunopotentiator to prepare a vaccine-immunized pig. After immunizing the vaccine containing the compound immunopotentiator, a window period for antibody production can be significantly shortened to 7 days; a LPB-ELISA antibody titer is significantly improved, and an antibody pass rate is significantly increased; an immune protection period is also significantly extended, at least up to 7 months; and the compound immunopotentiator is safe, and has no obvious side effects of immunity. | 2020-08-20 |
20200261571 | TRITERPENE SAPONIN ANALOGUES - The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases and cancers. | 2020-08-20 |
20200261572 | MESSENGER RIBONUCLEIC ACIDS FOR ENHANCING IMMUNE RESPONSES AND METHODS OF USE THEREOF - The disclosure features isolated mRNAs encoding a polypeptide that enhances immune responses to an antigen(s) of interest, such as polypeptides that activate Type I interferon pathway signaling or NFkB signaling, including mRNAs comprising one or more modified nucleobase. The disclosure also features methods of using the same, for example, for enhancing immune responses when administered with an antigen(s) of interest, such as to stimulate anti-cancer immune responses or anti-pathogen immune responses. | 2020-08-20 |
20200261573 | COMBINATION OF C-MET INHIBITOR WITH ANTIBODY MOLECULE TO PD-1 AND USES THEREOF - The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1), and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination. | 2020-08-20 |
20200261574 | ANTI-CD40 ANTIBODIES AND USES THEREOF - The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies. | 2020-08-20 |
20200261575 | MULTIMERIC IL-15-BASED MOLECULES - The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule. | 2020-08-20 |
20200261576 | APOPTOTIC CELL-MEDIATED INDUCTION OF ANTIGEN SPECIFIC REGULATORY T-CELLS FOR THE THERAPY OF AUTOIMMUNE DISEASES IN ANIMALS AND HUMANS - The invention provides methods of tolerizing or treating a subject suffering from an autoimmune or autoinflammatory disease or disorder to an antigen associated with the autoimmune disease or disorder. The invention also features kits for carrying out the methods of the invention. | 2020-08-20 |
20200261577 | METHODS OF PREVENTING SECONDARY INFECTIONS - A method of treating or preventing a disease associated with a secondary infection in a subject infected with a pathogen is provided. The method comprises administering to the subject a therapeutically effective amount of an anti-pathogenic agent directed towards the pathogen and a therapeutically effective amount of an agent which down-regulates at least one extracellular matrix-associated polypeptide. | 2020-08-20 |
20200261578 | GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) ANTIBODIES AND METHODS OF USE THEREOF - The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor) Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer. | 2020-08-20 |
20200261579 | CANCER STARVATION THERAPY - The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction. | 2020-08-20 |
20200261580 | Photodynamic Therapy Method for Skin Disorders - The present invention is directed to methods of treating diseases and disorders of the skin (e.g., acne) with heat-enabled photodynamic therapy (HEPT). Methods of treating acne, non-melanoma skin cancer (NMSC), actinic keratosis (AK) or disseminated superficial actinic porokeratosis (DSAP) using red light photodynamic therapy on heat-treated skin. | 2020-08-20 |
20200261581 | INJECTABLE IBUPROFEN FORMULATION - The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition. | 2020-08-20 |
20200261582 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE - Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided. | 2020-08-20 |
20200261583 | THERMOGEL FORMULATION FOR COMBINATION DRUG DELIVERY - The invention provides a drug delivery system for a combination of therapeutic agents. The system includes a water soluble biodegradable ABA-type triblock copolymer that possesses thermosensitive gelation properties. The system can form a stable thermogel that includes a combination of therapeutic agents including, for example, rapamycin, paclitaxel, and 17-AAG. After administration to a subject, the drugs are released at a controlled rate from the thermogel, which biodegrades into non-toxic components. The polymer system can also function to increase the solubility and stability of drugs in the composition. | 2020-08-20 |
20200261584 | STABILIZED PROTEIN GEL PREPARATION - To provide a protein preparation which enables reduction of aggregation and a stable long-time preservation, in a protein preparation having a high concentration or a protein preparation susceptible to aggregation. The protein preparation is a gel preparation which is thixotropic and in which an included protein is protected from a physical or chemical stress, is inhibited from aggregation, and thereby stably exists. | 2020-08-20 |
20200261586 | TOPICAL TETRACYCLINE COMPOSITIONS - A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force. | 2020-08-20 |
20200261587 | POLYMER-SUNITINIB CONJUGATES - The invention relates to (among other things) polymer-sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over sunitinib in unconjugated form. | 2020-08-20 |
20200261588 | INTERMEDIATE DRUG WITH SYNERGISTIC ANTICANCER ACTIVITY AND POLYETHYLENE GLYCOL-COUPLED SYNERGISTIC ANTICANCER DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF - Disclosed are an intermediate drug having synergistic anticancer activity and a polyethylene glycol-coupled synergistic anticancer drug, and a method preparing therefor and use thereof. The intermediate drug has the general structural formula of (I), and the polyethylene glycol-coupled synergistic anticancer drug has the general structural formula of (II). The drugs achieve the combined medication of various anticancer drugs and avoid the toxic reaction caused by the interaction among the drugs or by the pharmacokinetics of the drugs when taking various anticancer drugs, facilitate overcoming the multidrug resistance of cancers, have a synergistic effect, and can be used for preparing anticancer medicaments and for treating cancers. | 2020-08-20 |
20200261589 | Use of a Syncytin for Targeting Drug and Gene Delivery to Regenerate Muscle Tissue - The invention relates to a pharmaceutical composition for targeting drug delivery including gene delivery to regenerating muscle tissue, comprising at least a therapeutic drug or gene, associated to a syncytin protein, and its use in the prevention and/or treatment of muscle injuries or diseases, in particular in gene therapy of said diseases using lentiviral vector particles or lentivirus-like particles pseudotyped with syncytin protein. | 2020-08-20 |
20200261590 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES - The present invention provides multi-armed high MW polymers containing hydrophilic groups conjugated to Factor VIII, and methods of preparing such polymers. | 2020-08-20 |
20200261591 | METHODS FOR PROMOTING TRAINED IMMUNITY WITH NANOBIOLOGIC COMPOSITIONS - The invention relates to therapeutic nanobiologic compositions and methods of treating patients who have cancer, by promoting trained immunity, which is the long-term increased responsiveness, the result of metabolic and epigenetic re-wiring of myeloid cells and their stem cells and progenitors in the bone marrow and spleen and blood induced by a primary insult, and characterized by increased cytokine excretion after re-stimulation with one or multiple secondary stimuli. | 2020-08-20 |
20200261592 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING - Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. | 2020-08-20 |
20200261593 | LINKER COMPOSITION COMPRISING SILICA-FORMING PEPTIDES - The present disclosure relates to the use of silica-forming peptides (SFPs) Volp1 and Salp1 for protein fusion tags for protein purification, silica formation and self-encapsulation, and controlled release of biomolecules. After preparing a fusion protein containing the Volp1 or Salp1 peptide at the C-terminal of the protein, the adsorption conditions for silica (SiO | 2020-08-20 |
20200261594 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE - The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody. | 2020-08-20 |
20200261595 | Oligomer Extended Insulin-FC Conjugates - This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to novel Fc fragments, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions. | 2020-08-20 |
20200261596 | Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same - Disclosed herein are compositions for treating and preventing diseases such as myeloma and lymphoma, where the compositions include a biocompatible, therapeutic polymeric nanoparticle having a boronate ester compound or a peptide boronic acid compound, and a biodegradable polymer. Methods of use of the therapeutic compositions are also disclosed. | 2020-08-20 |
20200261597 | BIOFUNCTIONALIZED NANOPARTICLES AND USES THEREOF IN ADOPTIVE CELL THERAPY - The present invention relates to biofunctionalized nanoparticles and uses thereof in adoptive cell therapy. In particular, the present invention relates to a nanoparticle comprising an amount of at least one antigen and an amount of at least one antibody having specificity for a B cell receptor wherein the antigen and antibody are attached to the surface of the nanoparticle. | 2020-08-20 |
20200261598 | ADENO-ASSOCIATED VIRAL VECTORS FOR TREATING MUCOLIPIDOSIS TYPE II - Provided herein are recombinant adeno-associated virus (rAAV) vectors comprising nucleic acid encoding N-acetyl-glucosamine-1-phosphate transferase, alpha and beta subunits (GNPTAB) and at least one AAV inverted terminal repeat (ITR). In some embodiments, the rAAV vectors may be included in a rAAV particle, which may be contained in pharmaceutical compositions and kits. These vectors, particles, compositions, and kits may find use, inter alia, in methods and uses related to treating mucolipidosis type II (ML II) or mucolipidosis type III (ML III) in a mammal, or related to increasing body size, bone mineral content, and/or bone mineral density in a mammal with mucolipidosis type II (ML II) or mucolipidosis type III (ML III). | 2020-08-20 |
20200261599 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF - The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. | 2020-08-20 |
20200261600 | METHOD FOR THE TREATMENT OR PREVENTION OF PAIN OR EXCESSIVE NEURONAL ACTIVITY OR EPILEPSY - The invention relates to methods for the treatment and/or prevention of pain, excessive neuronal activity, or epilepsy, and to gene therapy vectors. In particular, the method comprises the overexpression of a CASPR2 polypeptide in sensory neurons of the individual and the gene therapy vector comprises a polynucleotide sequence that encodes a CASPR2 polypeptide or a variant thereof. | 2020-08-20 |
20200261601 | METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXBETA REDUCTASE - The present disclosure provides methods of treating a human having a disease or disorder that would benefit from increasing platelet counts. The method involves inhibiting the enzyme activity of biliverdin IXβ reductase (BLVRB) activity or inhibiting the expression of BLVRB gene. | 2020-08-20 |
20200261602 | COMPOSITIONS AND METHODS FOR ENHANCED FLUORESCENCE - This disclosure relates to the field of fluorescent dyes, and in particular, compositions and methods for increasing fluorescent signals and the reduction of fluorescent quenching. | 2020-08-20 |
20200261603 | NOVEL ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT - The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment. | 2020-08-20 |
20200261604 | Diagnosis-treatment Integrated nano-probe for 19F-MR/fluorescence multi-mode molecular imaging and drug-loading and preparation method and application of nano-probe - The present invention provides a | 2020-08-20 |
20200261605 | FUNCTIONALIZED LIPOSOMES FOR IMAGING MISFOLDED PROTEINS - Phospholipid-polymer-aromatic conjugates comprising binding ligands, liposome compositions including the phospholipid-polymer-aromatic conjugates, and binding ligands having an affinity for misfolded proteins are described. The phospholipid-polymer-aromatic conjugate may be represented by Structural Formula I: PL-AL-HP-X-BL (I). In Formula I, PL is a phospholipid, AL is an aliphatic linkage, HP is hydrophilic polymer, X is a link between the phospholipid-polymer and the binding ligand, and BL is polycyclic aromatic compound that functions as a binding ligand. The liposomal compositions may be useful for the imaging of misfolded and/or aggregated proteins. | 2020-08-20 |
20200261606 | METHODS AND SYSTEMS FOR PRODUCING, USING, AND ADMINISTERING HYPERPOLARIZED FLUIDS - Methods of and systems for making a hyperpolarized fluid are provided, which include exposing a fluid and parahydrogen to a catalyst. The hyperpolarized fluid can be introduced to a subject. The hyperpolarized fluid can be included in methods of imaging a subject. Also provided are methods that use the hyperpolarized fluids for detecting protein ligand interactions and for enhancing the NMR signals of biopolymers having chemically exchangeable protons. | 2020-08-20 |
20200261607 | DOTMP KIT FORMULATIONS FOR RADIOISOTOPES - This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two-part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression or bone marrow ablation. | 2020-08-20 |
20200261608 | STANDALONE UV-C SANITIZING APPARATUS AND METHOD - A standalone UV-C sanitizing apparatus and method is provided that is operable to sanitize and disinfect a user's hands or protective gloves. The apparatus includes a housing with light emitting diodes (LEDs) positioned to emit ultraviolet (UV-C) light connected to a circuit board which are individually connected to a power source. The apparatus is configured so that when the user positions the hands or gloves under the housing, the UV-C light is emitted for a predetermined period of time based on the distance to the hands and the power output of the LEDs. The UV-C light is emitted at a wavelength suitable to kill, destroy, or reduce growth of microorganisms/germs. The housing can be configured with a sensor to detect motion under the housing and include a limiter hand guard. | 2020-08-20 |
20200261609 | METHOD FOR PRESSURIZING A STEAM STERILIZATION CHAMBER - A method for pressurizing a sterilization chamber of a steam sterilizer with a controlled rate of pressure change. Pressure is increased in the sterilization chamber by opening a steam-to-chamber valve for a pulse duration during each of a plurality of time PERIODS needed to reach a target pressure value. During each time PERIOD, the steam-to-chamber valve is moved to an open state for the duration of the pulse. An error value indicative of the difference between a Theoretical Pressure and a Measured Pressure is determined at the end of each PERIOD. This error value is used to determine the duration of the pulse for the subsequent PERIOD, thereby maintaining a desired rate of pressure change in the sterilization chamber. | 2020-08-20 |
20200261610 | STERILIZABLE INDWELLING CATHETERS - According to an aspect of the invention, an indwelling catheter is provided which comprises a catheter shaft. The catheter either comprises a light source or is adapted to receive light from a light source, and is configured such that light is transmitted from the light source into the catheter shaft. Moreover, the catheter shaft is formed of a polymeric material that transmits a quantity of light from the light source that is effective to inactivate microorganisms on a surface of the catheter shaft upon activation of the light source. For example, the light may inactivate the microorganisms directly or in conjunction with a photosensitizer. According to another aspect of the invention, a sterilization method is provided, which comprises activating the light source while the catheter is inserted in a subject. | 2020-08-20 |
20200261611 | SYSTEMS AND METHODS FOR DISINFECTION - A disinfecting system includes a housing. An ultraviolet light (UV) source is secured to the housing and configured to emit UV light for disinfection of a target. A processor is secured to the housing in communication with the UV light source. The processor is configured to activate the UV light source for a selected amount of time suitable for disinfection of the target. | 2020-08-20 |
20200261612 | HYGIENE SYSTEM FOR A PORTABLE PACKAGED FOOD CONTAINER - A system may automatically conduct hygiene cycles for a confined space such an interior space of a box suitable for storing and/or carrying packaged food. The system may include a hygiene device that can be attached to the box to conduct the hygiene cycles and a user interface device that can wirelessly communicate with the hygiene device to control the conduction of the hygiene cycles. The system may also automatically collect information related to the hygiene cycles using the hygiene device and transmit the collected information to a network directly or through the user interface device. | 2020-08-20 |
20200261613 | Fragrance Dispenser Having a Disposable Piezoelectric Cartridge with a Snap-In Bottle Containing Aromatic Liquid - A dispenser includes a housing having a power source. A piezoelectric cartridge is installable within the housing and includes a cartridge body, a piezoelectric discharge nozzle supported by the cartridge body and a micro-perforated vibratory plate. The discharge nozzle is powered by the dispenser when the piezoelectric cartridge is installed within the housing of the dispenser. A fragrance bottle is supported by the cartridge body. The cartridge body further has a liquid fragrance path from the bottle to the piezoelectric nozzle. The path includes a channel with a wick. The wick is in contact with the vibratory plate of the piezoelectric discharge nozzle. | 2020-08-20 |
20200261614 | VASCULAR GRAFT AND METHODS FOR SEALING A VASCULAR GRAFT - Disclosed herein are a vascular graft and a method for sealing a vascular graft. The method generally includes applying a hydrogel sealant to the vascular graft thereby sealing the graft, wherein the hydrogel sealant is prepared from material selected from the group consisting of plant sourced material, synthetic material, or a combination thereof. In some embodiments, the hydrogel sealant may be prepared from albumin and a crosslinking agent or from poly(ethylene)oxide and a poly(amine). | 2020-08-20 |
20200261615 | Tissue-Adhesive Sealant Device - The invention is directed to a biodegradable tissue-adhesive device for sealing tissue, said device comprising a tissue-adhesive layer which comprises a blend of a tissue-reactive polymer and a biodegradable carrier polyurethane according to the formula of A-B-C-B | 2020-08-20 |
20200261616 | DELIVERY SYSTEMS BASED ON HYDROGEL COMPOSITIONS AND METHODS THEREOF - The invention provides a novel, versatile degradable hydrogel composition, and methods thereof, with precisely tunable stiffness, plasticity (e.g., degree of covalent vs. physical crosslinks) and predictive disintegration rates degradation, allowing controlled disintegration and release of therapeutic cells or pharmaceuticals and/or in vitro 3D cell expansion. | 2020-08-20 |
20200261617 | NERVE CONDUITS - The invention provides bioresorbable nerve guidance conduits made from polymer blends which include polyhydroxyalkanoates (PHAs). In particular, the invention provides nerve guidance conduits having a body which comprises a polymer blend comprising: (a) from 60 to 98 wt. % of a first component which is a PHA copolymer comprising two or more different medium chain length hydroxyalkanoate monomer units; and (b) from 2 to 40 wt. % of a second component which is either a PHA homopolymer containing a short chain length hydroxyalkanoate monomer unit, or a polylactide (PLA). The invention further relates to polymer blends comprising (a) and (b). | 2020-08-20 |
20200261618 | LIQUID TISSUE GRAFT - The present disclosure relates to methods and compositions comprising dissociated buccal mucosa tissue that are useful for treating a wound. Kits for preparing the liquid suspension of dissociated buccal mucosa tissue and treating the wound are also disclosed. | 2020-08-20 |
20200261619 | Construct Having Structure and Cell Mass Linked Together - The present invention provides a system for artificially inducing and regulating “tissue interactions” among multiple tissues. A construct for transplantation into a living body, which comprises a structure and a cell mass linked to each other, the structure being an object having a three-dimensional structure and capable of mimicking or resembling a structure and/or a function of the living body. | 2020-08-20 |
20200261620 | METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR - Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain. | 2020-08-20 |
20200261621 | ELECTRIFIED COMPOSITE MEMBRANE WITH EXTRACELLULAR MATRIX ELECTRICAL TOPOLOGY CHARACTERISTICS, AND PREPARATION METHOD THEREOF - The invention involves a kind of electrified composite membrane with extracellular matrix electrical topology characteristics and its preparation method, which resolves the technical problems of poor matching of electric characteristics and natural extracellular matrix characteristics in the existing materials and limited restoration effect of materials. The invention provides a kind of electrified composite membrane with extracellular matrix electrical topology characteristics mainly composed of ferroelectric polymer matrix and piezoelectric active fiber fillings. By regulating the draw ratio, content and of piezoelectric active fiber and thickness of composite film, the invention can realized the flexibility of film material and electrical topological features of bionic extracellular matrix, with proper tissue adhesion and good electric adaptability and high clinical operability. | 2020-08-20 |
20200261622 | COMPOSITES FOR LOAD-BEARING APPLICATIONS - A load-bearing bone fixation composite includes a polymer matrix, a plurality of polymer fibers aligned along a common axis and disposed in the polymer matrix, wherein the polymer matrix binds the surface of the polymer fibers, and a plurality of high aspect ratio nanorods coating at least a portion of each of the polymer fibers, wherein the long axis of at least a portion of the nanorods is aligned with the common axis, and wherein the high aspect nanorods have an aspect ratio of 10 or greater. Further included is a bone fixation device including the foregoing composite. A method of bone fixation comprises affixing the foregoing composite to a site of a load-bearing bone fracture, or maxillofacial bone fracture. Also included are methods of making the composites. | 2020-08-20 |
20200261623 | BIODEGRADABLE BIOMIMETICS OF GROWTH PLATE CARTILAGE FOR THE TREATMENT OF PHYSEAL INJURIES - The present invention relates to the unexpected discovery of 3D printed biomimetics of growth plate cartilage and methods using the same for the treatment of growth plate defects. In certain embodiments, the methods prevent the growth of bony bars at the site of growth plate injury, thereby preventing growth arrest and/or deformity. | 2020-08-20 |
20200261624 | SOFT TISSUE REPAIR IMPLANTS COMPRISING HYDROXYBUTYRATE - Articles and methods involving soft tissue repair implants comprising 2-hydroxybutyrate, 3-hydroxybutyrate, 4-hydroxybutyrate, and/or their conjugate acids are generally provided. The 2-hydroxybutyrate, 3-hydroxybutyrate, 4-hydroxybutyrate, and/or the conjugate acid(s) of 2-hydroxybutyrate, 3-hydroxybutyrate, and 4-hydroxybutyrate may be provided in a therapeutically-effective amount for reducing or preventing microbial infection. | 2020-08-20 |
20200261625 | LYOPHILIZED MOLDABLE IMPLANTS CONTAINING AN OXYSTEROL - Provided is a lyophilized implant configured to fit at or near a bone defect to promote bone growth, the lyophilized implant containing a biodegradable polymer in an amount of about 0.1 wt. % to about 20 wt. % of the implant, mineral particles in an amount from about 0.1 wt. % to about 75 wt. % of the implant, and an oxysterol in an amount of about 5 wt. % to about 90 wt. % of the implant. Methods of making and using the implant are further provided. | 2020-08-20 |
20200261626 | METHODS OF SYNTHESIS FOR A THIOKETAL DIOL - A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis(2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided. | 2020-08-20 |
20200261627 | USE OF PEBA HAVING LONG BLOCKS FOR THE MANUFACTURE OF ALL OR PART OF A CATHETER - The present invention relates to the use of a copolymer containing polyether blocks and polyamide blocks for manufacturing an inflatable catheter element, such as a catheter balloon, with improved bursting strength, in which said copolymer has the following characteristics: a number-average molecular mass of the PE blocks greater than 500 g/mol, and a number-average molecular mass of the PA blocks greater than 10,000 g/mol. | 2020-08-20 |
20200261628 | MOLECULAR IMPRINTED BIOFUNCTIONAL DEVICE - An apparatus and method are disclosed for a biofunctional molecular imprint medical device configured to remain in permanent or temporary contact with a body comprising a supportive structure, a surface material that receives and retains a molecular imprint and that is positioned to contact a body tissue or other substance during use, a molecular imprint of a bioactive molecule wherein an imprinted cavity is of a bioactive molecule that catalyzes the promotion or suppression biological processes and at least one of a semiconductor, a nanoparticle quantum dot, a nano-island, and a quantum wire, wherein the nanoparticle quantum dot, nano-island, or quantum wire produces an electron wave function configuration that dynamically reconfigures the electron charge distribution within the molecular imprint, enabling tuning of the imprinted cavity. | 2020-08-20 |
20200261629 | SENSOR POSITIONING AND OPTICAL SENSING FOR SENSOR ENABLED WOUND THERAPY DRESSINGS AND SYSTEMS - In some embodiments, a wound monitoring and/or therapy apparatus can include a wound dressing configured to be positioned over a wound. The wound dressing can support one or more sensors. The one or more sensors can include an optical sensor array cluster, which can include an optical sensor and single light source. In some embodiments, the wound dressing can include a substantially stretchable wound contact layer that includes a wound facing side and a non-wound facing side opposite the wound facing side, the wound facing side configured to be positioned in contact with a wound. The non-wound facing side of the wound contact layer can support a plurality of electronic components and a plurality of electronic connections that connect at least some of the plurality of the electronic components. The electronic components can include one or more sensors configured to obtain measurements of the wound or the periwound, or both. | 2020-08-20 |
20200261630 | SYSTEM AND METHOD FOR COLLECTING PLASMA - A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container. | 2020-08-20 |
20200261631 | BLOOD TRANSFUSION KIT AND SYSTEM AND MWTHOD - In a blood transfusion system (a blood transfusion kit, a blood transfusion kit for emergency blood transfusion, or a method of using a blood transfusion kit), a flow path through which blood flows is formed using a tube having a channel therein. The flow path includes: a first path that connects an upstream path and a downstream path and has a leukocyte removal filter removing leukocytes at an intermediate position of the channel; and a second path that connects the upstream path and the downstream path and bypasses the leukocyte removal filter. | 2020-08-20 |
20200261632 | System for Aseptic Collection and Enteral Delivery - A container for collecting, storing and dispensing fluid, as in enteral feeding and/or medication deliver to neonatal infants. The container includes a hollow tube with a body, a first end, a second end, and an outer diameter. The hollow tube is configured to receive a movable plunger that advances and retracts therein to define a variable contained volume. The container also includes a sealing head assembly removably mounted at an end of the hollow tube. The sealing head assembly has a diameter or outside dimension that is substantially similar or identical to a corresponding outside diameter or dimension of the hollow tube, so that the container lies flat within the receiver of an enteral feeding pump. | 2020-08-20 |